SBMFF News and Press, Sino Biopharmaceutical Ltd

Sino Biopharm (1177.HK) Announces 2023 Annual Results HONG KONG, Mar 29, 2024 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the...

Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results HONG KONG, Aug 25, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical ...

2023-08-13 07:00:00 ET Summary BeiGene and Bristol-Myers Squibb have completed the breakup of their partnership, with BeiGene regaining shares worth $340 million. Gracell Biotechnologies raised $100 million in a private placement to support the development of its CAR-T therapies. ...

2023-07-09 09:15:00 ET Summary Moderna is setting up operations in Shanghai to develop and manufacture mRNA products for the Chinese market, investing up to $1 billion. F-star Therapeutics has formed a collaboration with Takeda to develop Fcab domains for immuno-oncology targets, ...

2023-06-04 07:30:00 ET Summary Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Shanghai’s Impact Therapeutics out-licensed global rights (ex-China) for t...

2023-04-10 00:38:00 ET Summary Duality Biologics (Suzhou) out-licensed global rights (ex-China) for two ADC candidates to BioNTech in a deal worth $170 million upfront and up to $1.5 billion in milestone payments. Shanghai HutchMed has completed the rolling submission of a US NDA ...

Sino Biopharm (1177.HK) Announces 2022 Annual Results HONG KONG, Mar 31, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the...

2023-03-26 23:52:00 ET Summary Highlightll Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. F-star, a Cambridge, UK biopharma, out-licensed global rights for a novel next-gen immuno-o...

2023-03-13 00:55:00 ET Summary Sino Biopharm was approved to close its $161 million all-cash acquisition of F-star, a Cambridge, UK company that develops bispecific antibodies. Harbour BioMed announced positive results from a China Phase III trial of its anti-FcRn mAb in patients ...

Summary The recent unprecedented national security incident created by suspected Chinese spy balloons and other aerial objects ratchet up geopolitical tensions and put F-star's acquisition by Sino Biopharmaceutical at significant risk. F-star's controversial acquisition by Sino Biopharm...